Pharma · Private company · Rahway, NJ, US
Merck Sharp & Dohme LLC
SEC CIK 0000064978
Track this companyFree. Adds Merck Sharp & Dohme LLC to your Dealase workspace and tells you when its record changes.
Clinical trials2525 recruiting or active
Pipeline programs75From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline75
- Acetaminophen (or equivalent)Phase 3 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- BevacizumabPhase 3 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- BomedemstatPhase 3 · Thrombocythemia, EssentialClinicalTrials.gov · fetched Nov 12, 2026
- CalderasibPhase 3 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- CarboplatinPhase 3 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- CarboplatinPhase 3 · Breast NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- CarboplatinPhase 3 · Endometrial CancerClinicalTrials.gov · fetched Nov 12, 2026
- CisplatinPhase 3 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- CisplatinPhase 3 · Endometrial CancerClinicalTrials.gov · fetched Nov 12, 2026
- CyclophosphamidePhase 3 · Diffuse Large B-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- Dexamethasone (or equivalent)Phase 3 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- DocetaxelPhase 3 · Endometrial CancerClinicalTrials.gov · fetched Nov 12, 2026
- DoxorubicinPhase 3 · Diffuse Large B-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- DoxorubicinPhase 3 · Breast NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- Enlicitide DecanoatePhase 3 · Heterozygous Familial Hypercholesterolemia (HeFH)ClinicalTrials.gov · fetched Nov 12, 2026
- GemcitabinePhase 3 · Triple Negative Breast NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- GemcitabinePhase 3 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- H1 receptor antagonistPhase 3 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- H2 receptor antagonistPhase 3 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- IV TulisokibartPhase 3 · Crohn's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- LenvatinibPhase 3 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- MK-4280Phase 3 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- MK-4280APhase 3 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- Nab-paclitaxelPhase 3 · Triple Negative Breast NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- OlaparibPhase 3 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- PaclitaxelPhase 3 · Breast NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- PaclitaxelPhase 3 · Endometrial CancerClinicalTrials.gov · fetched Nov 12, 2026
- PaclitaxelPhase 3 · Triple Negative Breast NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 3 · Endometrial CancerClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 3 · Breast NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 3 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 3 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 3 · Triple Negative Breast NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- Pembrolizumab (+) Berahyaluronidase alfaPhase 3 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- PemetrexedPhase 3 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- PrednisonePhase 3 · Diffuse Large B-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- Rescue MedicationPhase 3 · Breast NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- Rescue MedicationPhase 3 · Triple Negative Breast NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- RituximabPhase 3 · Diffuse Large B-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- Rituximab BiosimilarPhase 3 · Diffuse Large B-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- Sacituzumab tirumotecanPhase 3 · Triple Negative Breast NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- Sacituzumab tirumotecanPhase 3 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- Sacituzumab tirumotecanPhase 3 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- Sacituzumab tirumotecanPhase 3 · Breast NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- Sacituzumab TirumotecanPhase 3 · Endometrial CancerClinicalTrials.gov · fetched Nov 12, 2026
- SC TulisokibartPhase 3 · Crohn's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- TulisokibartPhase 3 · Crohn DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Vericiguat suspensionPhase 3 · Heart FailureClinicalTrials.gov · fetched Nov 12, 2026
- Vericiguat tabletPhase 3 · Heart FailureClinicalTrials.gov · fetched Nov 12, 2026
- Zilovertamab vedotinPhase 3 · Diffuse Large B-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- BelzutifanPhase 2 · Pheochromocytoma/ParagangliomaClinicalTrials.gov · fetched Nov 12, 2026
- BevacizumabPhase 2 · Ovarian Cancer RecurrentClinicalTrials.gov · fetched Nov 12, 2026
- CabazitaxelPhase 2 · Prostatic Neoplasms, Castration-ResistantClinicalTrials.gov · fetched Nov 12, 2026
- CarboplatinPhase 2 · Ovarian Cancer RecurrentClinicalTrials.gov · fetched Nov 12, 2026
- CetuximabPhase 2 · Malignant NeoplasmClinicalTrials.gov · fetched Nov 12, 2026
- DexamethasonePhase 2 · Prostatic Neoplasms, Castration-ResistantClinicalTrials.gov · fetched Nov 12, 2026
- DocetaxelPhase 2 · Prostatic Neoplasms, Castration-ResistantClinicalTrials.gov · fetched Nov 12, 2026
- Fludrocortisone acetatePhase 2 · Prostatic Neoplasms, Castration-ResistantClinicalTrials.gov · fetched Nov 12, 2026
- Intismeran autogenePhase 2 · Malignant MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- MK-1084Phase 2 · Malignant NeoplasmClinicalTrials.gov · fetched Nov 12, 2026
- MK-3120Phase 2 · Bladder CancerClinicalTrials.gov · fetched Nov 12, 2026
- MK-3120Phase 2 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- MK-3120Phase 2 · Urothelial CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- OlaparibPhase 2 · Prostatic Neoplasms, Castration-ResistantClinicalTrials.gov · fetched Nov 12, 2026
- OpevesostatPhase 2 · Prostatic Neoplasms, Castration-ResistantClinicalTrials.gov · fetched Nov 12, 2026
- PaclitaxelPhase 2 · Ovarian Cancer RecurrentClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Malignant MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Malignant NeoplasmClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Urothelial CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Ovarian Cancer RecurrentClinicalTrials.gov · fetched Nov 12, 2026
- Raludotatug DeruxtecanPhase 2 · Ovarian Cancer RecurrentClinicalTrials.gov · fetched Nov 12, 2026
- Rescue medicationPhase 2 · Malignant NeoplasmClinicalTrials.gov · fetched Nov 12, 2026
- Rescue MedicationPhase 2 · Ovarian Cancer RecurrentClinicalTrials.gov · fetched Nov 12, 2026
- Sacituzumab tirumotecan (sac-TMT)Phase 2 · Malignant NeoplasmClinicalTrials.gov · fetched Nov 12, 2026
- Zilovertamab vedotinPhase 2 · Urothelial CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)PHASE2 · RECRUITING · started Dec 19, 2025ClinicalTrials.gov NCT07252739 · fetched Nov 12, 2026
- A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)PHASE1_PHASE2 · RECRUITING · started Dec 9, 2025ClinicalTrials.gov NCT07222488 · fetched Nov 12, 2026
- A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)PHASE3 · RECRUITING · started Oct 8, 2025ClinicalTrials.gov NCT07190248 · fetched Nov 12, 2026
- A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)PHASE2_PHASE3 · RECRUITING · started Aug 21, 2025ClinicalTrials.gov NCT07058077 · fetched Nov 12, 2026
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)PHASE3 · RECRUITING · started Jun 30, 2025ClinicalTrials.gov NCT06966700 · fetched Nov 12, 2026
- A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)PHASE2 · ACTIVE_NOT_RECRUITING · started May 29, 2025ClinicalTrials.gov NCT06961006 · fetched Nov 12, 2026
- A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)PHASE3 · RECRUITING · started May 22, 2025ClinicalTrials.gov NCT06952504 · fetched Nov 12, 2026
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).PHASE1_PHASE2 · RECRUITING · started Apr 15, 2025ClinicalTrials.gov NCT06843447 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)PHASE3 · RECRUITING · started Apr 9, 2025ClinicalTrials.gov NCT06824467 · fetched Nov 12, 2026
- A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)PHASE1_PHASE2 · RECRUITING · started Mar 25, 2025ClinicalTrials.gov NCT06818643 · fetched Nov 12, 2026
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)PHASE3 · RECRUITING · started Mar 16, 2025ClinicalTrials.gov NCT06841354 · fetched Nov 12, 2026
- A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)PHASE3 · RECRUITING · started Jan 27, 2025ClinicalTrials.gov NCT06717347 · fetched Nov 12, 2026
- Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)PHASE3 · RECRUITING · started Nov 25, 2024ClinicalTrials.gov NCT06651281 · fetched Nov 12, 2026
- A Community Health Education Intervention for Increasing Community-driven Actions to Reduce the Cancer Burden in Western New YorkNA · RECRUITING · started Nov 16, 2024ClinicalTrials.gov NCT06681077 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)PHASE3 · RECRUITING · started Jun 5, 2024ClinicalTrials.gov NCT06430801 · fetched Nov 12, 2026
- A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)PHASE3 · RECRUITING · started May 24, 2024ClinicalTrials.gov NCT06345729 · fetched Nov 12, 2026
- A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)PHASE3 · RECRUITING · started May 23, 2024ClinicalTrials.gov NCT06351631 · fetched Nov 12, 2026
- Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started May 20, 2024ClinicalTrials.gov NCT06353386 · fetched Nov 12, 2026
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)PHASE3 · RECRUITING · started Apr 3, 2024ClinicalTrials.gov NCT06312137 · fetched Nov 12, 2026
- Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)PHASE2_PHASE3 · RECRUITING · started May 31, 2023ClinicalTrials.gov NCT05714085 · fetched Nov 12, 2026
- Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)PHASE3 · ACTIVE_NOT_RECRUITING · started Jan 11, 2023ClinicalTrials.gov NCT05555732 · fetched Nov 12, 2026
- A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Nov 16, 2022ClinicalTrials.gov NCT05562830 · fetched Nov 12, 2026
- Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)PHASE2 · RECRUITING · started Aug 12, 2021ClinicalTrials.gov NCT04924075 · fetched Nov 12, 2026
- Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)PHASE3 · RECRUITING · started Aug 21, 2018ClinicalTrials.gov NCT03486873 · fetched Nov 12, 2026
- Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin LymphomaPHASE2 · RECRUITING · started Aug 1, 2018ClinicalTrials.gov NCT03618550 · fetched Nov 12, 2026